Evidence map›Paper›PMID 36031405›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial.

Manjusha Gaglani, Sara S Kim, Allison L Naleway, Min Z Levine, Laura Edwards, Kempapura Murthy, Kayan Dunnigan, Tnelda Zunie, Holly Groom, Sarah Ball and 13 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03722589 (Randomized Open-Label Trial to Compare the Immunogenicity of Cell Culture-Based and Recombinant Unadjuvanted Quadrivalent Influenza Vaccines to Conventional Egg-Based Unadjuvanted Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03722589 phase4completednot on this map

Randomized Open-Label Trial to Compare the Immunogenicity of Cell Culture-Based and Recombinant Unadjuvanted Quadrivalent Influenza Vaccines to Conventional Egg-Based Unadjuvanted Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2018 to 2020Enrolled944ConditionsInfluenzaArmsFlublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Trial
  2. Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Trial
  3. Trial
  4. Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Manjusha GaglaniDepartment of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.ORCID 0000-0002-3952-9230
Sara S KimInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Allison L NalewayCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
Min Z LevineInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laura EdwardsAbt Associates, Atlanta, Georgia, USA.
Kempapura MurthyDepartment of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.
Kayan DunniganDepartment of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.
Tnelda ZunieDepartment of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.
Holly GroomCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
Sarah BallAbt Associates, Atlanta, Georgia, USA.
Zuha JeddyAbt Associates, Atlanta, Georgia, USA.
Danielle HuntAbt Associates, Atlanta, Georgia, USA.
Meredith G WesleyAbt Associates, Atlanta, Georgia, USA.ORCID 0000-0003-3408-0523
Suryaprakash SambharaInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Shivaprakash GangappaInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Lauren GrantInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Weiping CaoInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
F Liaini GrossInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Margarita MishinaInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Alicia M FryInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mark G ThompsonInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Fatimah S DawoodInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Brendan FlanneryInfluenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · USSchulman, Ronca & Bucuvalas · USBaylor Scott & White Health · USKaiser Permanente Center for Health Research · USTemple College · USWestat (United States) · US

Funding

CDC HHS 75D30118F02850
6 · The paper itself

Abstract

backgroundAntibody responses to non-egg-based standard-dose cell-culture influenza vaccine (containing 15 µg hemagglutinin [HA]/component) and recombinant vaccine (containing 45 µg HA/component) during consecutive seasons have not been studied in the United States.

methodsIn a randomized trial of immunogenicity of quadrivalent influenza vaccines among healthcare personnel (HCP) aged 18-64 years over 2 consecutive seasons, HCP who received recombinant-HA influenza vaccine (RIV) or cell culture-based inactivated influenza vaccine (ccIIV) during the first season (year 1) were re-randomized the second season of 2019-2020 (year 2 [Y2]) to receive ccIIV or RIV, resulting in 4 ccIIV/RIV combinations. In Y2, hemagglutination inhibition antibody titers against reference cell-grown vaccine viruses were compared in each ccIIV/RIV group with titers among HCP randomized both seasons to receive egg-based, standard-dose inactivated influenza vaccine (IIV) using geometric mean titer (GMT) ratios of Y2 post-vaccination titers.

resultsY2 data from 414 HCP were analyzed per protocol. Compared with 60 IIV/IIV recipients, 74 RIV/RIV and 106 ccIIV/RIV recipients showed significantly elevated GMT ratios (Bonferroni corrected P < .007) against all components except A(H3N2). Post-vaccination GMT ratios for ccIIV/ccIIV and RIV/ccIIV were not significantly elevated compared with IIV/IIV except for RIV/ccIIV against A(H1N1)pdm09.

conclusionsIn adult HCP, receipt of RIV in 2 consecutive seasons or the second season was more immunogenic than consecutive egg-based IIV for 3 of the 4 components of quadrivalent vaccine. Immunogenicity of ccIIV/ccIIV was similar to that of IIV/IIV. Differences in HA antigen content may play a role in immunogenicity of influenza vaccination in consecutive seasons. CLINICAL TRIALS REGISTRATION: NCT03722589.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesSmallpox VaccineAdultAntibodies, ViralCell Culture TechniquesDelivery of Health CareHemagglutination Inhibition TestsHumansInfluenza A Virus, H3N2 SubtypeUnited StatesVaccinationVaccines, CombinedVaccines, InactivatedVaccines, SyntheticAntibodies, ViralInfluenza VaccinesSmallpox VaccineVaccines, CombinedVaccines, InactivatedVaccines, SyntheticFlublok QuadrivalentFlucelvax Quadrivalenthealthcare personnelimmunogenicityinfluenza vaccines

Identifiers

PMID36031405
PMCPMC9907492
OpenAlexW4293414238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.